Journal articles: 'PETT'

1

Naylor, M. N., and H. K. Kemp. "Basil Warwick Pett." British Dental Journal 196, no. 8 (April 2004): 507. http://dx.doi.org/10.1038/sj.bdj.4811188.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Berglind, Natalie. "I'm Not Millie by Mark Pett." Bulletin of the Center for Children's Books 73, no. 3 (2019): 136. http://dx.doi.org/10.1353/bcc.2019.0791.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Jo, In Young, Jeong Won Lee, Woo Chul Kim, Chul Kee Min, Eun Seog Kim, Seung-Gu Yeo, and Sang Mi Lee. "Relationship between Changes in Myocardial F-18 Fluorodeoxyglucose Uptake and Radiation Dose after Adjuvant Three-Dimensional Conformal Radiotherapy in Patients with Breast Cancer." Journal of Clinical Medicine 9, no. 3 (March 2, 2020): 666. http://dx.doi.org/10.3390/jcm9030666.

Full text

Abstract:

This study aimed to assess the relationship between radiation dose and changes in the irradiated myocardial F-18 fluorodeoxyglucose (FDG) uptake after radiotherapy (RT) in breast cancer patients. The data of 55 patients with left and 48 patients with right breast cancer who underwent curative surgical resection and adjuvant three-dimensional conformal RT and staging (PET1), post-adjuvant chemotherapy (PET2), post-RT (PET3), and surveillance (PET4) FDG positron emission tomography/computed tomography (PET/CT) were retrospectively reviewed. The median interval between PET1 and curative surgical resection, between the end of adjuvant chemotherapy and PET2, between the end of RT and PET3, and between the end of RT and PET4 were five days, 13 days, 132 days, and 353 days, respectively. The myocardial-to-blood pool uptake ratio was measured in all patients. For patients with left breast cancer, the 30 Gy- (30 Gy) and 47.5 Gy-irradiated myocardium-to-low-irradiated myocardium (47.5 Gy) FDG uptake ratios were additionally measured. There were no differences in the myocardial-to-blood pool uptake ratios between left and right breast cancer on all PET scans. For left breast cancer, higher 30 Gy and 47.5 Gy uptake ratios were observed on PET3 than on PET1 and PET2. Both uptake ratios decreased on PET4 compared to PET3, but, were still higher compared to PET1. On PET3 and PET4, the 47.5 Gy were higher than the 30 Gy uptake ratios, while there were no differences between them on PET1 and PET2. Although the whole myocardium FDG uptake showed no significant change, the irradiated myocardium FDG uptake significantly increased after RT and was related to radiation dose to the myocardium in breast cancer patients. These results might be an imaging evidence that supports the increased risk of heart disease after RT in patients with left breast cancer.

APA, Harvard, Vancouver, ISO, and other styles

4

Coronado-Poggio, Mónica, Ana Cristina Hernandez-Martinez, M. Pilar Sarandeses, Montse Cortés-Romera, Marc Simó-Perdigó, Xavier Setoain, Amanda Rotger, et al. "Central Review of PET/TC: First Spanish Experience in a Phase 2 Randomized Trial in Diffuse Large B-Cell Lymphoma (DLBCL) Patients." Blood 126, no. 23 (December 3, 2015): 5042. http://dx.doi.org/10.1182/blood.v126.23.5042.5042.

Full text

Abstract:

Abstract Background: Positron emission tomography / computed tomography with fluorodeoxyglucose (FDG-PET/CT) is widely accepted for staging and for end treatment assessment in patients with DLBCL, and has demonstrated to have prognostic impact when used to evaluate early response to chemotherapy (CT) in this group of patients. In the last years, many changes in the way of interpreting PET/CT have been proposed, both for interim and for end of treatment (Barrington SG, J Clin Oncol 2014;32:3048-3058) We present preliminary data of the first Spanish centralized PET/CT review in a Phase 2 randomized trial in young patients with poor prognosis diffuse large B-cell lymphoma (DLBCL), which compares 6 cycles of RCHOP versus 6 cycles of a modified RCHOP regimen, Bortezomid-R CAP (BRCAP). ClinicalTrials.gov Identifier: NCT01848132. The main objective is to evaluate concordance between reviewers in interim and final PET, in order to stablish the best criteria for PET/CT assessment. PET2 ability to predict PET4 result is also analyzed. Methods: A blinded, prospective, centralized review in real time of PET/CT images was realized by the GELTAMO PET network. For each patient, images of basal (PET0), interim PET2 and PET4 and final PET after completion of chemotherapy (PET 6) were sent to a central platform, and then analysed by the review panel composed of seven expert nuclear medicine physicians. PET2 and PET4 were interpreted visually based on Deauville criteria (considering scores 4 and 5 as positive), and also semiquantitavely (considering a positive PET2 when ΔSUVmax≤66% and a positive PET4 when ΔSUVmax≤70%). PET6 was interpreted following Deauville criteria. Final result of every PET/CT was defined as positive or negative by the central review panel. When discordance between visual and semiquantitative analysis was found in interim PET, semiquantitative method was determinant of final result. A positive PET4 result determined dropped out from trial. Concordance between all readers was analysed using Cohen's kappa coefficient. Results: Of the first 76 patients that underwent PET/CT, 64 patients completed PET0, PET2 and PET4; 34 patients underwent PET0, PET2, PET4 and PET6. In the central review, 44/64 patients (69%) were PET2(-) and 20/64 (31%) were PET2(+); 44/64 (69%) were PET4(-) and 20/64 (31%) PET4(+); 21/34 (62%) were PET6(-) and 13/34 (38%) were PET6(+). We found 43 patients with negative PET2 and PET4, 19 patients with positive PET2 and PET4, 1 patient with positive PET2 and negative PET4, and 1 patient with negative PET2 and positive PET4. PET2 result was predictive of PET4 (p<0.001). Concordance between reviewers for PET2 using visual assessment was good (median kappa=0,74) and very good using semiquantitative analysis (median kappa: 0,83). Concordance between reviewers for PET4 using visual assessment was good (kappa=0,72) and very good when semiquantitative analysis was used (median kappa=0,87). For PET6, concordance between readers was moderate (kappa=0.45). Conclusion: In this homogeneus group of patients, a centralized semiquantitative analysis of interim PET after 2 and 4 cycles of chemotherapy improves concordance between readers in comparison with visual analysis. When semiquantitative method is used, PET2 is predictive of PET4 result. In the same way, visual analysis of PET6 using Deauville criteria seems to have a worse concordance between readers, but more patients need to be analyzed to confirm this result. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

5

Park, Hye, Eun Han, Joo O, Byung-Ock Choi, Gyeongsin Park, Seung-Eun Jung, Seung-Ah Yahng, Ki-Seong Eom, and Seok-Goo Cho. "Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma." Diagnostics 10, no. 12 (November 24, 2020): 1002. http://dx.doi.org/10.3390/diagnostics10121002.

Full text

Abstract:

Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) after one cycle of standard chemotherapy in patients with diffuse large B cell lymphoma (DLBCL) was assessed. Prospectively enrolled 51 patients had four PET/CT studies using the same protocol and system: at baseline and after one, three, and six cycles of chemotherapy (PET0, PET1, PET3, PET6). The PET1 and PET6 Deauville five-point score (D5PS) agreed in 60.8%, while PET3 and PET6 D5PS agreed in 90.2%. The absolute and percent changes of peak standard uptake value corrected for lean body mass (SULpeak) compared to baseline were significantly different between PET1 and PET3 (p = 0.001, p < 0.001) and PET1 and PET6 (p = 0.002, p = 0.001), but not between PET3 and PET6 (p = 0.276, p = 0.181). The absolute SULpeak from PET1 predicted treatment failure with accuracy of 78.4% (area under the curve 0.73, p = 0.023). D5PS, SULpeak, and metabolic tumor volume (MTV) were not statistically different between responders versus non-responders, or the one year disease-free versus relapse groups. D5PS and PERCIST responses showed 100% agreement at end-of-therapy. In conclusion, the responses after three and six cycles of therapy showed high degree of agreement. D5PS or MTV after one cycle of chemotherapy could not predict response or one-year disease-free status, but the SULpeak from PET1 was associated with response to first line therapy in DLBCL. Deauville and PERCIST criteria show high concordance.

APA, Harvard, Vancouver, ISO, and other styles

6

Hulick, Jeannette. "The Girl and the Bicycle by Mark Pett." Bulletin of the Center for Children's Books 67, no. 9 (2014): 473. http://dx.doi.org/10.1353/bcc.2014.0317.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Pettman, Dominic. "When Lulu met the Centaur: Photographic traces of creaturely love." NECSUS. European Journal of Media Studies 4, no. 1 (January 1, 2015): 127–44. http://dx.doi.org/10.5117/necsus2015.1.pett.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Petterson, Daphne, Carolien Gravesteijn, and Concetta Peschier. "De kracht van alledaags ouderschap." Pedagogiek 37, no. 1 (April 21, 2017): 27–46. http://dx.doi.org/10.5117/ped2017.1.pett.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Petterson, Anne, and Claire Weeda. "Over nationale identiteitsvorming, herinneren en vergeten." Tijdschrift voor geschiedenis 132, no. 2 (September 1, 2019): 281–90. http://dx.doi.org/10.5117/tvgesch2019.2.007.pett.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Adamowicz, Marek, Zbigniew Krzemiński, and Paweł Stec. "Dual Active Bridge (DAB) DC-DC converter for multilevel propulsion converters for electrical multiple units (EMU)." MATEC Web of Conferences 180 (2018): 04002. http://dx.doi.org/10.1051/matecconf/201818004002.

Full text

Abstract:

Semiconductor power devices made from silicon carbide (SiC) reached a level of technology enabling their widespread use in power converters. Two different approaches to implementation of modern traction converters in electric multiple units (EMU) have been presented in recent years: (i) 3.3-kV SiC MOSFET-based three-level PWM inverter with regenerative braking and (ii) 6.5-kV IGBT-based fourquadrant power electronic traction transformer (PETT). The former has successfully reached optimized dimensions and efficiency but still requires a bulky line frequency transformer for multisystem applications. The latter characterizes inherent galvanic isolation from AC traction, which is realized by cascaded system of power electronic cells containing medium frequency transformers (MFT). The downsizing of the 6.5-kV IGBT-based cells is, however, problematic. The present paper proposes a different approach, that involves the use of a fast switching 1.2-kV SiC MOSFETS. The SiC-based PETT proposed in the paper is dedicated first for the DC traction. For multi-system application the input voltage of the proposed PETT can be adjusted using weight-optimized adjusting autotransformer. Thanks to utilization of fast-switching SiCbased power modules the weight and size of the power electronic cells can be optimized in a convenient way.

APA, Harvard, Vancouver, ISO, and other styles

11

Forest, Emmanuelle, Benoît Lenzen, and Marie Öhman. "Teaching traditions in physical education in France, Switzerland and Sweden: A special focus on official curricula for gymnastics and fitness training." European Educational Research Journal 17, no. 1 (June 14, 2017): 71–90. http://dx.doi.org/10.1177/1474904117708889.

Full text

Abstract:

The aim of this paper is to identify and discuss similarities and differences between the curricula for physical education (PE) in secondary schools in Sweden, France and the canton of Geneva (Switzerland) in the light of PE teaching traditions (PETTs). Teaching traditions concern ideas about the goals of school disciplines and therefore about the kind of learning pupils are expected to acquire. The paper focuses more specifically on two subjects, gymnastics and fitness training, because these physical activities are liable to highlight the similarities and differences across contexts in terms of didactic transposition. A content analysis of current curriculum materials of the three countries was conducted taking the following dimensions into account: (a) the general structure of the curriculum texts; (b) the general recommendations; and (c) the learning outcomes expected from the pupils in terms of knowledge and values, with examples of contents in gymnastics and fitness training. The results show the entanglement of various PETTs in each country: PETT as Sport-Techniques primarily shapes French and Swiss-Genevan curricula, PETT as Health Education is more present in Sweden and, to a lesser extent, in Switzerland, while PETT as Physical Culture Education tends to be more visible in France.

APA, Harvard, Vancouver, ISO, and other styles

12

Adamowicz, Marek, and Janusz Szewczyk. "SiC-Based Power Electronic Traction Transformer (PETT) for 3 kV DC Rail Traction." Energies 13, no. 21 (October 24, 2020): 5573. http://dx.doi.org/10.3390/en13215573.

Full text

Abstract:

The design of rolling stock plays a key role in the attractiveness of the rail transport. Train design must strictly meet the requirements of rail operators to ensure high quality and cost-effective services. Semiconductor power devices made from silicon carbide (SiC) have reached a level of technology enabling their widespread use in traction power converters. SiC transistors offering energy savings, quieter operation, improved reliability and reduced maintenance costs have become the choice for the next-generation railway power converters and are quickly replacing the IGBT technology which has been used for decades. The paper describes the design and development of a novel SiC-based DC power electronic traction transformer (PETT) intended for electric multiple units (EMUs) operated in 3 kV DC rail traction. The details related to the 0.5 MVA peak power medium voltage prototype, including the electrical design of the main building blocks are presented in the first part of the paper. The second part deals with the implementation of the developed SiC-based DC PETT into a regional train operating on a 3 kV DC traction system. The experimental results obtained during the testing are presented to demonstrate the performance of the developed 3 kV DC PETT prototype.

APA, Harvard, Vancouver, ISO, and other styles

13

Ravichandran, V., and R. K. Agrawal. "Predicting anti-HIV activity of PETT derivatives: CoMFA approach." Bioorganic & Medicinal Chemistry Letters 17, no. 8 (April 2007): 2197–202. http://dx.doi.org/10.1016/j.bmcl.2007.01.103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Toshima, Naoki, and Yukihide Shiraishi. "Combination of nanoparticles and carbon nanotubes for organic hybrid thermoelectrics." Pure and Applied Chemistry 92, no. 6 (June 25, 2020): 967–76. http://dx.doi.org/10.1515/pac-2019-1109.

Full text

Abstract:

AbstractCarbon nanotubes (CNTs) are usually very expensive, but inexpensive CNTs have been mass-produced by a super-growth (SG) method. The SG-CNTs, however, have many defects resulting in a low conductivity, which is a disadvantage of the SG-CNTs. We discovered that even the defective SG-CNTs can provide a good thermoelectric performance by forming ternary hybrid films made of the SG-CNTs, nanoparticles (NPs) of a conducting polymer complex, poly(nickel 1,1,2,2-ethenetetrathiolate) (PETT) and poly(vinyl chloride) (PVC). The good thermoelectric performance of the ternary film (PETT-NP/SG-CNT/PVC) was possibly attributed to the defect repair effect in addition to the bridging effect of the PETT-NPs among the CNTs. In order to confirm this new concept, we attempted the deposition of metal NPs at the defects of the SG-CNTs. We initially made a physical mixture of palladium (Pd) NPs and the SG-CNTs in dispersions to cover the SG-CNT defects with the Pd-NPs. The obtained films showed only a slight improvement in electrical conductivity. Chemical reduction of the Pd ions in the dispersion of the SG-CNTs, on the other hand, provided hybrids with an enhanced electrical conductivity, thus, use as thermoelectric materials. The thermoelectric figure-of-merit was estimated to be ∼0.3, which is a relatively high value for organic hybrid materials.

APA, Harvard, Vancouver, ISO, and other styles

15

Bell, Frank W., Amanda S. Cantrell, Marita Hoegberg, S. Richard Jaskunas, Nils Gunnar Johansson, Christopher L. Jordan, Michael D. Kinnick, Peter Lind, and John M. Morin. "Phenethylthiazolethiourea (PETT) Compounds, a New Class of HIV-1 Reverse Transcriptase Inhibitors. 1. Synthesis and Basic Structure-Activity Relationship Studies of PETT Analogs." Journal of Medicinal Chemistry 38, no. 25 (December 1995): 4929–36. http://dx.doi.org/10.1021/jm00025a010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Gill, Robin. "Douglas Ellory Pett, The Healing Tradition of the New Testament." Theology 119, no. 4 (June 20, 2016): 296–97. http://dx.doi.org/10.1177/0040571x16640234l.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Öberg, B., C. Åhgren, B. Classon, P. Engelhardt, M. Högberg, N. G. Johansson, J. Kangasmetsä, et al. "Anti-HIV activities of new PETT compounds in cell cultures." Antiviral Research 26, no. 3 (March 1995): A236. http://dx.doi.org/10.1016/0166-3542(95)94717-g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Stevenson, Deborah. "I Eat Poop: A Dung Beetle Story by Mark Pett." Bulletin of the Center for Children's Books 75, no. 1 (2021): 28. http://dx.doi.org/10.1353/bcc.2021.0477.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Cantrell, Amanda S., Per Engelhardt, Marita Högberg, S. Richard Jaskunas, Nils Gunnar Johansson, Christopher L. Jordan, Jussi Kangasmetsä, et al. "Phenethylthiazolylthiourea (PETT) Compounds as a New Class of HIV-1 Reverse Transcriptase Inhibitors. 2. Synthesis and Further Structure−Activity Relationship Studies of PETT Analogs." Journal of Medicinal Chemistry 39, no. 21 (January 1996): 4261–74. http://dx.doi.org/10.1021/jm950639r.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Högberg, Marita, Christer Sahlberg, Per Engelhardt, Rolf Noréen, Jussi Kangasmetsä, Nils Gunnar Johansson, Bo Öberg, et al. "Urea−PETT Compounds as a New Class of HIV-1 Reverse Transcriptase Inhibitors. 3. Synthesis and Further Structure−Activity Relationship Studies of PETT Analogues." Journal of Medicinal Chemistry 42, no. 20 (October 1999): 4150–60. http://dx.doi.org/10.1021/jm990095j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Högberg, Marita, Christer Sahlberg, Per Engelhardt, Rolf Noréen, Jussi Kangasmetsä, Nils Gunnar Johansson, Bo Öberg, et al. "Urea−PETT Compounds as a New Class of HIV-1 Reverse Transcriptase Inhibitors. 3. Synthesis and Further Structure−Activity Relationship Studies of PETT Analogues." Journal of Medicinal Chemistry 43, no. 2 (January 2000): 304. http://dx.doi.org/10.1021/jm990572y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Pettoello, Renato. "Lo strumento degli dei. La filosofia dell�arte di Schelling tra Romanticismo e Classicismo." Colloquium 9788879168151 (October 2017): 59–70. http://dx.doi.org/10.7359/815-2017-pett.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Högberg, Marita, Per Engelhardt, Lotta Vrang, and Hong Zhang. "Bioisosteric modification of PETT-HIV-1 RT-inhibitors: synthesis and biological evaluation." Bioorganic & Medicinal Chemistry Letters 10, no. 3 (February 2000): 265–68. http://dx.doi.org/10.1016/s0960-894x(99)00675-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Sabet, Razieh, Afshin Fassihi, and Behzad Moeinifard. "QSAR study of PETT derivatives as potent HIV-1 reverse transcriptase inhibitors." Journal of Molecular Graphics and Modelling 28, no. 2 (September 2009): 146–55. http://dx.doi.org/10.1016/j.jmgm.2009.05.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Eertink, J. J., C. N. Burggraaff, M. W. Heymans, U. Dührsen, A. Hüttmann, C. Schmitz, S. Müller, et al. "Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients." Blood Advances 5, no. 9 (May 4, 2021): 2375–84. http://dx.doi.org/10.1182/bloodadvances.2021004467.

Full text

Abstract:

Abstract Interim 18F-fluorodeoxyglucose positron emission tomography (Interim-18F-FDG-PET, hereafter I-PET) has the potential to guide treatment of patients with diffuse large B-cell lymphoma (DLBCL) if the prognostic value is known. The aim of this study was to determine the optimal timing and response criteria for evaluating prognosis with I-PET in DLBCL. Individual patient data from 1692 patients with de novo DLBCL were combined and scans were harmonized. I-PET was performed at various time points during treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Scans were interpreted using the Deauville score (DS) and change in maximum standardized uptake value (ΔSUVmax). Multilevel Cox proportional hazards models corrected for International Prognostic Index (IPI) score were used to study the effects of timing and response criteria on 2-year progression-free survival (PFS). I-PET after 2 cycles (I-PET2) and I-PET4 significantly discriminated good responders from poor responders, with the highest hazard ratios (HRs) for I-PET4. Multivariable HRs for a PET-positive result at I-PET2 and I-PET4 were 1.71 and 2.95 using DS4-5, 4.91 and 6.20 using DS5, and 2.93 and 4.65 using ΔSUVmax, respectively. ΔSUVmax identified a larger proportion of poor responders than DS5 did. For all criteria, the negative predictive value was >80%, and positive predictive values ranged from 30% to 70% at I-PET2 and I-PET4. Unlike I-PET1, I-PET3 discriminated good responders from poor responders using DS4-5 and DS5 thresholds (HRs, 2.94 and 4.67, respectively). I-PET2 and I-PET4 predict good response equally during R-CHOP therapy in DLBCL. Optimal timing and response criteria depend on the clinical context. Good response at I-PET2 is suggested for de-escalation trials, and poor response using ΔSUVmax at I-PET4 is suggested for randomized trials that are evaluating new therapies.

APA, Harvard, Vancouver, ISO, and other styles

26

Fernando, Sumal, Michael Lin, Trang Thanh Pham, Shanley Chong, Emilia Ip, Karen Wong, Wei Chua, Weng Ng, Peter Lin, and Stephanie Lim. "Prognostic utility of serial 18F-FDG-PET/CT in patients with locally advanced rectal cancer who underwent tri-modality treatment." British Journal of Radiology 93, no. 1105 (January 2020): 20190455. http://dx.doi.org/10.1259/bjr.20190455.

Full text

Abstract:

Objective: This study explored the value of serial 18-fludeoxyglucose-positron emission tomography (18F-FDG-PET/CT) in predicting disease-free survival (DFS) in locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiation (NCRT) and surgery. Methods: We prospectively studied 46 patients with LARC who underwent NCRT and surgery. 18F-FDG-PET/CT scans were performed at three time-points before surgery (pre-NCRT-PET1, during NCRT-PET2 and following completion of NCRT-PET3). The following semi-quantitative PET parameters were analysed at each time point: maximum standardized uptake value (SUVmax), SUVmean, metabolic tumour volume (MTV) and tumour lesion glycolysis (TLG). Absolute and percentage changes in these parameters were analysed between time points. Statistical analysis consisted of median tests, Cox regression and Kaplan–Meier analysis for DFS. Results: The median follow-up time was 24 months. A reduction in PET parameters showed statistically significant differences for patients with recurrence compared to those without; percentage changes in MTV between PET1 and PET3 (cut-off: 87%, p = 0.023), percentage changes in TLG between PET1 and PET3 (cut-off: 94%, p = 0.02) and absolute change in MTV PET1 and PET2 (cut-off: 10.25, p = 0.001). An absolute reduction in MTV between PET1 and PET3 (p=0.013), a percentage reduction in TLG between PET1 and PET2 (p=0.021), SUVmax and SUVmean at PET2 (p = 0.01, p = 0.027 respectively)were also prognostic indicators of recurrence. MTV percentage change between PET1 and PET2 and SUVmean percentage change between PET1 and PET3 were also trending towards significance (p = 0.052, p = 0.053 respectively). Conclusion: Serial 18F-FDG-PET/CT is a potentially reliable non-invasive method to predict recurrence in patients with LARC. Volumetric parameters were the best predictors. This could allow risk-stratification in patients who may benefit from conservative management. Advances in knowledge: This paper will add to the literature in risk-stratifying patients with LARC based on prognosis, using 18F-FDG-PET/CT. This may improve patient outcomes by selecting suitable candidates for conservative management.

APA, Harvard, Vancouver, ISO, and other styles

27

Ren, Jingshan, Jonathan Diprose, Jonathan Warren, Robert M. Esnouf, Louise E. Bird, Shinji Ikemizu, Martin Slater, et al. "Phenylethylthiazolylthiourea (PETT) Non-nucleoside Inhibitors of HIV-1 and HIV-2 Reverse Transcriptases." Journal of Biological Chemistry 275, no. 8 (February 25, 2000): 5633–39. http://dx.doi.org/10.1074/jbc.275.8.5633.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Hunter, William C., Sally Barton-Arwood, Andrea Jasper, Renee Murley, and Tarol Clements. "Utilizing the PPET Mnemonic to Guide Classroom-Level PBIS for Students With or at Risk for EBD Across Classroom Settings." Beyond Behavior 26, no. 2 (June 27, 2017): 81–88. http://dx.doi.org/10.1177/1074295617711398.

Full text

Abstract:

In this article, the authors discuss how the emphasis on classroom-level Positive Behavior Interventions and Supports strategies can establish a foundation for an efficient classroom management program and be utilized as a resource. The strategies described are physical classroom, procedures and rules, explicit timing, and transition (PETT mnemonic). Each strategy can be particularly useful in assisting novice and veteran teachers provide instruction to students with emotional and behavioral disorders within inclusive or self-contained classrooms.

APA, Harvard, Vancouver, ISO, and other styles

29

Turner, Richard H. "Clergy Funds and Episcopal Control—Was John Stanford Maligned?" Recusant History 27, no. 1 (May 2004): 51–85. http://dx.doi.org/10.1017/s0034193200031174.

Full text

Abstract:

John Stanford, missioner with the Hunlokes at Wingerworth in Derbyshire from 1692 to 1737, is nowadays remembered for one event. ‘In a huff and a pett’, the received story goes, he—being unable in 1725 properly to account as administrator for the Common Fund of the secular clergy of the Midland District—handed it over to his vicar apostolic, John Talbot Stonor.To those familiar with the traditions of clergy fund independence, this peevish act must appear self-evident treachery. However—just how soundly based is the story?

APA, Harvard, Vancouver, ISO, and other styles

30

Bajaj, S., S. S. Sambi, and A. K. Madan. "Predicting anti-HIV activity of phenethylthiazolethiourea (PETT) analogs: computational approach using Wiener's topochemical index." Journal of Molecular Structure: THEOCHEM 684, no. 1-3 (September 2004): 197–203. http://dx.doi.org/10.1016/j.theochem.2004.01.052.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Hoegberg, Marita, Per Engelhardt, Lotta Vrang, and Hong Zhang. "ChemInform Abstract: Bioisosteric Modification of PETT-HIV-1 RT-Inhibitors: Synthesis and Biological Evaluation." ChemInform 31, no. 20 (June 8, 2010): no. http://dx.doi.org/10.1002/chin.200020087.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Fan, Jiayu, Zhibin Zhao, Jinqiang Zhang, Cheng Peng, Xinling Tang, Xuebao Li, and Xiang Cui. "Electromagnetic Disturbance Characteristics and Influence Factors of PETT Oscillation in High-Voltage IGBT Devices." IEEE Transactions on Power Electronics 36, no. 4 (April 2021): 4116–24. http://dx.doi.org/10.1109/tpel.2020.3019502.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Song, Lulu, Qianlai Zhuang, Yunhe Yin, Shaohong Wu, and Xudong Zhu. "Intercomparison of Model-Estimated Potential Evapotranspiration on the Tibetan Plateau during 1981–2010." Earth Interactions 21, no. 11 (December 1, 2017): 1–22. http://dx.doi.org/10.1175/ei-d-16-0020.1.

Full text

Abstract:

Abstract Potential evapotranspiration (PET), the maximum evapotranspiration rate under unlimited water supply, reflects the capacity for transpiration flow and plant primary production. Numerous models have been developed to quantify PET, but there are still large uncertainties in PET estimations. In this study, the authors conducted spatially explicit estimations of daily PET from 1981 to 2010 for eight different land-cover types on the Tibetan Plateau by applying three types of PET models including a combination model (Penman–Monteith), a radiation-based model (Priestley–Taylor), and a temperature-based model (Thornthwaite). This study found that the PET estimated by Thornthwaite model (PETT) was lower than those estimated by Priestley–Taylor (PETPT) and Penman–Monteith models (PETPM). Penman–Monteith model gave the highest estimates of PET on annual and daily scales. The mean annual PET for the whole plateau estimated by these three models varied from 675.1 to 700.5 mm yr−1, and daily PET varied from 1.33 to 1.92 mm day−1. The spatial pattern of PETT did not agree with the PETPT and PETPM, while the latter two agreed well with each other. Because of different model structures and dominant meteorological drivers, the interannual variability of PET varied significantly among the models. PETPT and PETPM showed a transition around 1993 since the dominant meteorological drivers were different before and after 1993. These disagreements among different models suggested that PET models with different algorithms should be used with caution. This study provided a validation to assist those undertaking PET estimations on the Tibetan Plateau.

APA, Harvard, Vancouver, ISO, and other styles

34

Howard, E. R., J. McDonald, Y. K. Seedat, and J. W. Baird. "John Leonard Dawson Susan Mary Barclay Edward ("Edoo") Michael Barker Andrew Dick Audrey Colquhoun-Pett." BMJ 319, no. 7207 (August 14, 1999): 456. http://dx.doi.org/10.1136/bmj.319.7207.456.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Arnett, Carroll D., Joanna S. Fowler, Alfred P. Wolf, Chyng-Yann Shiue, and Daniel W. McPherson. "[]-N-: The radioligand of choice for pett studies of the dopamine receptor in human brain." Life Sciences 36, no. 14 (April 1985): 1359–66. http://dx.doi.org/10.1016/0024-3205(85)90041-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Grove, Simon. "Pest pets." New Scientist 208, no. 2790 (December 2010): 29. http://dx.doi.org/10.1016/s0262-4079(10)63054-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Algrin, Caroline, Nathalie Bérenger, Sylvie Chevret, Laetitia Vercellino, Cédric de Bazelaire, Pauline Brice, David Sibon, et al. "Interim-Positron Emission Tomography with [18F]Fluorodeoxyglucose (interim-PET) Evaluation In Mediastinal Lymphoma Including Hodgkin Lymphoma (HL) and Primary Mediastinal Large B-Cell Lymphoma (PMBL)." Blood 116, no. 21 (November 19, 2010): 2860. http://dx.doi.org/10.1182/blood.v116.21.2860.2860.

Full text

Abstract:

Abstract Abstract 2860 Introduction. Histological lymphoma diagnosis of adult patients with bulky mediastinal mass is either HL or PMBL, two distinct diseases with a specific outcome. PET interpretation is often difficult for mediastinal lymphoma because of the volume of the tumor and the presence of blood pool. No specific criteria for interpretation of interim-PET have yet been defined in this clinical entity. The purpose of this study was to investigate the prognostic value of qualitative and semiquantitative evaluations of interim-PET in mediastinal lymphoma. Methods. We retrospectively included 72 patients with either HL (n=48) or PMBL (n=24), previously untreated, aged under 60 at diagnosis and who underwent at least one interim-PET evaluation. Patients with sub-diaphragmatic or medullar localisations of lymphoma were excluded. All PET scans were reviewed. Qualitative evaluation included global visual evaluation (GVE) (positive or negative) and 5 points-scale (5PS). Semiquantitative evaluation consisted in maximum standardized uptake value (SUVmax) and SUVmax reduction between the baseline PET (PET0) and the evaluation performed after two (PET2) or four (PET4) cycles of chemotherapy. Prognostic impact was evaluated on the event-free survival (EFS), defined as disease progression/first relapse (n=18) or death (n=2). ROC (Receiver Operating Characteristic) curve was used to assess the value of SUVmax reduction in discriminating future deaths or relapses, based on area under the curve (AUC). The “best“ cut-off that provides both the lowest false positive and the lowest false negative rates was computed. Results. Median age was 29 (24 - 35), 60% male. Tumoral mass was more than 7.5 cm in 70% of the patients, and M/T ratio>= 0.35 in 79%. Median SUVmax at baseline, PET2 and PET4 were 12.8 (4.1;33.2), 1.9 (1.7;3.1), and 2.4 (1.7;3.1), respectively. With a median follow-up at 24 months, 2-year event-free survival (EFS) was 67%, without significant difference between HL and PMBL (p=0.98). Except for ECOG performance status in PMBL, neither clinical nor biological feature was predictive for EFS. Using GVE, a negative PET2 (n=36/59) and PET4 (n=24/34), were achieved in 61% and 71%, respectively. GVE and 5PS have a significant negative predictive value (NPV) at PET2 (HR=3.2, 95%CI: 1.2–8.2; p=0.012, and HR=1.9, 95%CI: 1.1–3.3, p=0.01) and at PET4 (HR=13.9, 95%CI: 3.5–55; p=0.0001, and 2.6, 95%CI: 1.5–4.7, p=0.001 respectively), with a 2-year estimated EFS of 69% for PET2-negative patients versus 51% for PET2-positive patients (p=0.012), and of 86% for PET4-negative patients versus 20% for PET4-positive patients (p=0.001). An optimal cut-off of 81% SUVmax reduction from PET0 to PET2 or PET4 yielded a 2-year estimated EFS of 70% in patients with reduction of more than 81%, versus 47% in those with reduction of 81% or less (p=0.004). In the HL subgroup, GVE and SUVmax reduction higher than 81% at PET2 (p=0.0001, p=0.015, respectively) and PET4 (p=0.004, p=0.015, respectively) showed significant prognostic values for EFS. In the PMBL subgroup, neither qualitative nor semiquantitative evaluation at PET2 was predictive for EFS. At PET4, GVE and 5PS were strongly predictive for EFS (p=0.005, p=0.0001). Patients with SUVmax reduction higher than 81% between PET0 and PET4 reached a 67% 2-year EFS, while patients with lower SUVmax reduction had only a 33% 2-year EFS (p=0.13). Conclusion. The cut-off value of SUVmax reduction estimated for predicting EFS with best accuracy in mediastinal lymphoma was 81%. Although the SUV semiquantification helps to reduce the number of false positives, visual global analysis had a significant negative predictive value in interim-PET in mediastinal lymphoma, with a possible very early prediction, as early as PET2 in HL, and a better prediction at PET4 than PET2 in PMBL. Disclosures: No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

38

D'cruz, Osmond J., and Fatih M. Uckun. "Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase." Journal of Enzyme Inhibition and Medicinal Chemistry 21, no. 4 (January 2006): 329–50. http://dx.doi.org/10.1080/14756360600774413.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Casasnovas, René-Olivier, Michel Meignan, Alina Berriolo-Riedinger, Stéphane Bardet, Anne Julian, Catherine Thieblemont, Pierre Vera, et al. "SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma." Blood 118, no. 1 (July 7, 2011): 37–43. http://dx.doi.org/10.1182/blood-2010-12-327767.

Full text

Abstract:

AbstractThe prognostic value of interim positron emission tomography (PET) interpreted according to visual criteria is a matter of debate in diffuse large B-cell lymphoma (DLBCL). Maximal standardized uptake value reduction (ΔSUVmax) may better predict outcome. To compare the prognostic value of both methods, we analyzed PET done at baseline (PET0) and after 2 (PET2) and 4 (PET4) cycles in 85 patients with high-risk DLBCL enrolled on a prospective multicenter trial. All images were centrally reviewed and interpreted visually according to the International Harmonization Project criteria and by computing ΔSUVmax between PET0 and PET2 (ΔSUVmaxPET0-2) or PET4 (ΔSUVmaxPET0-4). Optimal cutoff to predict progression or death was 66% for ΔSUVmaxPET0-2 and 70% for ΔSUVmaxPET0-4. Outcomes did not differ significantly whether PET2 and PET4 were visually positive or negative. Inversely, ΔSUVmaxPET0-2 analysis (> 66% vs ≤ 66%) identified patients with significantly different 2-year progression-free survival (77% vs 57%; P = .0282) and overall survival (93% vs 60%; P < .0001). ΔSUVmaxPET0-4 analysis (> 70% vs ≤ 70%) seemed even more predictive for 2-year progression-free survival (83 vs 40%; P < .0001) and overall survival (94% vs 50%; P < .0001). ΔSUVmax analysis of sequential interim PET is feasible for high-risk DLBCL and better predicts outcome than visual analysis. The trial was registered at http://clinicaltrials.gov as NCT00498043.

APA, Harvard, Vancouver, ISO, and other styles

40

Nusbaumer, Louis, Phillip Cribb, and Laurent Gautier. "Nervilia Gassneri Börge Pett. from Africa is Conspecific with the Malagasy N. Lilacea Jum. & H. Perrier." Candollea 66, no. 1 (January 2011): 127–30. http://dx.doi.org/10.15553/c2011v661a14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Politte, David G., Gary R. Hoffman, David E. Beecher, David C. Ficke, Timothy J. Holmes, and M. M. Ter-Pogossian. "Image-Reconstruction of Data from Super PETT I: A First-Generation Time-of-Flight Positron-Emission Tomograph." IEEE Transactions on Nuclear Science 33, no. 1 (1986): 428–34. http://dx.doi.org/10.1109/tns.1986.4337136.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Ahgren, C., K. Backro, F. W. Bell, A. S. Cantrell, M. Clemens, J. M. Colacino, J. B. Deeter, J. A. Engelhardt, M. Hogberg, and S. R. Jaskunas. "The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase." Antimicrobial Agents and Chemotherapy 39, no. 6 (June 1, 1995): 1329–35. http://dx.doi.org/10.1128/aac.39.6.1329.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Hinshelwood, R. D., and Craig Fees. "Joint responsibility as an attitude of mind (working alongside) a letter by David Wills in the PETT archives." Therapeutic Communities: The International Journal of Therapeutic Communities 36, no. 3 (September 14, 2015): 186–91. http://dx.doi.org/10.1108/tc-01-2014-0001.

Full text

Abstract:

Purpose – The purpose of this paper is to present a previously unpublished letter from children’s therapeutic community pioneer David Wills to his younger colleague in the field, Robert Laslett, which attempts to define and summarise a lifetime’s understanding of the essence of a therapeutic environment. This raises concepts and issues of relevance to current theory and practice in therapeutic environments. Design/methodology/approach – The authors contextualise the 1977 letter from David Wills before presenting it verbatim, with clarifying annotations relating to people and events. They then analyse and discuss the fundamental arguments presented in the letter, with relevance to current thinking and practice. Findings – The approach presented by David Wills to his younger colleague is deeply challenging to current concepts and understandings of therapeutic environments and the role in the therapeutic task of subjectivity and “attitude of mind”. The view is taken that this presents “a great question for wide debate, right now”. Research limitations/implications – Very little historical/analytical research has taken place into the experiences, thinking and practice of those who have built the diverse fields of therapeutic communities and environments, not least because history disturbs and challenges the present. This paper opens a small window on the vast resources which are available, and indicates something of the rich potential for debate and practical challenge Experts by Experience pose to living and, hopefully, learning practitioners to day. Practical implications – Questions are raised: the debate they engender should eventuate into clearer, better grounded, more radical, and more effective practice. Social implications – This letter challenges assumptions about the role and nature of the “therapeutic attitude” and the place of subjectivity, with profound implications for the therapeutic enterprise itself, and the organisation of therapeutic environments, as well as policy, assessment and regulation regimes. Originality/value – The use of previously unpublished archive material opens living questions to examination from a different perspective, widening the debate to include voices of expertise and experience which are generally, consciously or unconsciously, excluded from it. Presenting the letter in its whole, and not excerpted as supporting evidence, allows the voice of expertise by experience to contribute directly to discussion and debate; unbalancing and enriching it.

APA, Harvard, Vancouver, ISO, and other styles

44

Glaser, Dale N. "Book Review of Making Sense of Factor Analysis. Marjorie A. Pett, Nancy R. Lackey, and John J. Sullivan." Structural Equation Modeling: A Multidisciplinary Journal 12, no. 1 (January 2005): 173–81. http://dx.doi.org/10.1207/s15328007sem1201_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Johansson, N. G., B. Classon, P. Engelhardt, M. Högberg, J. Kangasmetä, P. Lind, C. Lopez, et al. "Optimization of antiviral and kinetic properties of PETT compounds, a class of potent non-nucleoside HIV-RT inhibitors." Antiviral Research 26, no. 3 (March 1995): A257. http://dx.doi.org/10.1016/0166-3542(95)94756-r.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Kyriakopoulos, Christos, Elisabeth I. Heath, Anna C. Ferrari, Scott Perlman, Tina M. Mayer, Mark N. Stein, Katharina Modelska, William Duggan, Robert Jeraj, and Glenn Liu. "Interlesional response assessment with 18F-sodium fluoride (18F-NaF) PET/CT in men with chemotherapy-naive bone metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA)." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 5036. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5036.

Full text

Abstract:

5036 Background: 18F-NaF PET/CT provides spatial and quantitative information on osteoblastic activity in men with bone mCRPC; thus, it can be used to assess interlesional response heterogeneity, a critical clinical issue. Here we assess the proportion of men treated with ENZA with responding lesions by 18F-NaF PET/CT at the time of prostate-specific antigen (PSA), standard radiographic, or clinical progression. Methods: Men with progressive mCRPC with ≥ 2 lesions on bone scintigraphy were enrolled and treated with ENZA 160 mg daily at 3 US sites. 18F-NaF PET/CT scans were obtained at baseline (PET1), week 13 (PET2), and at the time of PSA progression (increase of ≥ 25% and ≥ 2.0 ng/mL above nadir), standard radiographic or clinical progression, or at 2 years without progression (PET3) using Quantitative Total Bone Imaging (QTBI). The primary endpoint was the proportion of men with ≥ 1 responding bone lesion (defined as a lesion with a total NaF standardized uptake value [SUV] less than baseline) on PET3. Evaluable men had scans at PET1 and PET3. Results: A total of 23 men (median age, 72 years [range, 51-93]; median PSA, 20.5 ng/mL [range, 3.9-133.6]) were enrolled. The study met its primary objective; 22 of 22 (100%) evaluable men had ≥ 1 responding bone lesion on QTBI at PET3. Total disease burden changed from a mean baseline SUV of 5700 (range, 507-22,850) to 5590 (range, 213-17,090) at PET2 and 6020 (range, 118-16,650) at PET3. The proportion of progressive lesions increased from a mean 7.8% (range, 0-29) at PET2 to 9.4% (range, 0-32) at PET3. Conclusions: Although PSA response with ENZA is high, many men experience a mixed response to treatment. While overall functional disease burden improves during treatment, an eventual increase in global burden is seen at the time of progression as measured by 18F-NaF PET/CT. At the primary endpoint analysis the proportion of progressing lesions is low, supporting both the hypothesis that a substantial number of lesions continue to benefit from treatment and the concept of treating beyond progression and selectively targeting nonresponding lesions while keeping patients on ENZA. Clinical trial information: NCT02384382.

APA, Harvard, Vancouver, ISO, and other styles

47

Tailor, Imran K., Bilal Btoosh, Shaimaa Hamdy, Shanker Raja, Mohammed O. Alharbi, Ibraheem H. Motabi, Nawal Faiez Alshehry, Mohammed S. Qureshi, Mubarak S. AlGhamdi, and Syed Ziauddin A. Zaidi. "Doublet Versus Triplet PET: Is END of Therapy PET Needed IF Interim PET Is Negative in Hodgkin'S or Diffuse Large B CELL Lymphoma?" Blood 128, no. 22 (December 2, 2016): 5354. http://dx.doi.org/10.1182/blood.v128.22.5354.5354.

Full text

Abstract:

Abstract Introduction: Baseline (PETb) and end of therapy (PETe) FDG PET is standard of care in the management of hodgkin's lymphoma (HL) and diffuse large B cell lymphoma (DLBCL). The role of interim PET (PETi) in HL is well established while its role in DLBCL is not well defined. We evaluated the utility of triPET (PETb, PETi and PETe ) in management of these two lymphomas. Methods: Retrospective review of PET archives revealed a total of 37 pts (HL=22, DLBCL=15). TriPET were acquired per accepted protocol. SUVmax and Deauville scores (DSc) were obtained from five target lesions, the average i.e. composite SUVmax & DSc were computed for each pt. Statistical analyses were performed with the composite maxSUV (cSUV) and Deauville scores (cDSc) (using EXCEL). Following statistics were performed (separately and combined in HL and DLBCL); mean+SD, PPV and NPV for complete response (CR) Vs. progressive disease (PD) on PETi using the following variables 1. cSUV and 2. cDSc and 3. delta change (DELT). Median progression free survival (PFS) was the clinical endpoint for response. Results: The mean PFS in our group was 17 and 15 months in HL and DLBCL respectively. Using cut off thresholds for intP to predict CR at cSUV<=2.0, , cDSC<=2.0 and DELT >=80%,. In HL: for cSUV- PPV 67%, NPV 95%; for DELT of cSUV PPV 100%, NPV 95%; for cDSC-PPV 30%, NPV 100%. In DLBCL: for cSUV- PPV 25%, NPV 100%; for DELT of cSUV PPV 33%, NPV 100%; for cDSC- PPV 50%, NPV 100%. Conclusion: The results from our series suggest that PETi has a role not only in HL but in DLBCL as well. Our modest cohort suggests that a negative PETi in DLBCL had a NPV of 100% across cSUV, cDSc and DELT, with regards to CR. Our data also suggests that PETe is not needed if PETi is -ve. While in HL subset, our results concur with results from other groups, this needs to be validated in a larger series. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

48

Casasnovas, Rene-Olivier, Michel Meignan, Alina Berriolo-Riedinger, Stephane Bardet, Anne Julian, Catherine Thieblemont, Pierre Vera, et al. "Interim [18F]Fluorodeoxyglucose Positron Emission Tomography SUVmax Reduction Is Superior to Visual Analysis to Predict Early patient's Outcome In Diffuse Large B-Cell Lymphoma." Blood 116, no. 21 (November 19, 2010): 320. http://dx.doi.org/10.1182/blood.v116.21.320.320.

Full text

Abstract:

Abstract Abstract 320 Purpose: Positron emision tomography with [18F]fluorodeoxyglucose (PET) performed after one to four cycles of chemotherapy could predict treatment outcome in diffuse large B cell lymphoma (DLBCL). However, suitable criteria to interpret interim PET remain to be established. Visual analysis was related to reproducibility concerns and false positive results in previous reports, and standardized uptake value (SUV) was proposed to improve interim PET accuracy. To compare the clinical usefulness of both methods, we analysed sequential interim PET according to visual and SUV criteria in a prospective multicenter phase II trial. Patients and method: From 2007 to April 2009, 113 patients with aaIPI 2–3 factors DLBCL were randomly assigned to receive an induction treatment with four cycles of either R-ACVBP or R-CHOP14 in the LNH2007-3B GELA trial. PET was done at baseline (PET0) and after 2 (PET2) and 4 cycles (PET4) of immuno-chemotherapy. All PET scans were centrally reviewed and interpreted using visual criteria. SUVmax reduction values between PET0 and PET2 (DSUVmaxPET0-2) or PET4 (DSUVmaxPET0-4) were available for 85 out of 113 patients. After using the receiver operating characteristics approach, patients with a DSUVmaxPET0-2 >66% were considered as good responders after 2 cycles and those with a DSUVmaxPET0-4 >70% were considered as good responder at end of induction treatment. Progression-free survival (PFS) was analyzed according to PET results based on visual criteria and DSUVmax. Results: Using visual analysis, respectively 34% and 49% of patients achieved a negative PET2 and PET4. An agreement between on-site and review panel was observed in 89% and 92% of cases for PET2 and PET4 leading to a kappa coefficient of 0.769 and 0.836 respectively. Seventy (82%) patients had a DSUVmaxPET0-2 > 66% and 74 (88%) had a DSUVmaxPET0-4 > 70%. Using DSUVmax analysis, 45 (78%) of the 58 PET2 positive patients and 33 (80%) of the 41 PET4 positive patients could be reclassified as good responder after 2 and 4 cycles of immuno-chemotherapy, respectively. PET2 and PET4 results based on visual criteria had no impact on PFS (p=0.99 and p=.077, respectively). By constrast, PET results based on DSUVmax better predicted PFS: patients with a DSUVmaxPET0-2 >66% had a better 1-year PFS than patients with a lower DSUVmaxPET0-2 (89% v 56%; p=0.0031). Similarly, patients with a DSUVmaxPET0-4 >70% reached a 90% 1-year PFS, while patients with a lower DSUVmaxPET0-4 only had 23% 1-year PFS (p<0.0001). Conclusion: Real-time central PET review is feasible in a multicenter setting. Visual analysis had a good reproducibility but was associated to an excess of positive results as well for PET2 as for PET4. SUVmax reduction between baseline and interim PET was more accurate than visual analysis to predict early outcome of patients treated for high risk DLBCL. It also appears to be the best method so far to assess PET response either at mid or end of induction treatment. Disclosures: No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

49

Venkatachalam, Taracad K., Chen Mao, and Fatih M. Uckun. "Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives." Biochemical Pharmacology 67, no. 10 (May 2004): 1933–46. http://dx.doi.org/10.1016/j.bcp.2004.01.019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Kyriakopoulos, Christos E., Elisabeth I. Heath, Anna Ferrari, Jamie M. Sperger, Anupama Singh, Scott B. Perlman, Alison R. Roth, et al. "Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide." Journal of Clinical Oncology 38, no. 31 (November 1, 2020): 3662–71. http://dx.doi.org/10.1200/jco.20.00348.

Full text

Abstract:

PURPOSE Intrapatient treatment response heterogeneity is under-recognized. Quantitative total bone imaging (QTBI) using 18F-NaF positron emission tomography/computed tomography (PET/CT) scans is a tool that allows characterization of interlesional treatment response heterogeneity in bone. Understanding spatial-temporal response is important to identify individuals who may benefit from treatment beyond progression. PATIENTS AND METHODS Men with progressive metastatic castration-resistant prostate cancer (mCRPC) with at least two lesions on bone scintigraphy were enrolled and treated with enzalutamide 160 mg daily (ClinicalTrials.gov identifier: NCT02384382 ). 18F-NaF PET/CT scans were obtained at baseline (PET1), week 13 (PET2), and at the time of prostate-specific antigen (PSA) progression, standard radiographic or clinical progression, or at 2 years without progression (PET3). QTBI was used to determine lesion-level response. The primary end point was the proportion of men with at least one responding bone lesion on PET3 using QTBI. RESULTS Twenty-three men were enrolled. Duration on treatment ranged from 1.4 to 34.1 months. In general, global standardized uptake value (SUV) metrics decreased while on enzalutamide (PET2) and increased at the time of progression (PET3). The most robust predictor of PSA progression was change in SUVhetero (PET1 to PET3; hazard ratio, 3.88; 95% CI, 1.24 to 12.1). Although overall functional disease burden improved during enzalutamide treatment, an increase in total burden (SUVtotal) was seen at the time of progression, as measured by 18F-NaF PET/CT. All (22/22) evaluable men had at least one responding bone lesion at PET3 using QTBI. CONCLUSION We found that the proportion of progressing lesions was low, indicating that a substantial number of lesions appear to continue to benefit from enzalutamide beyond progression. Selective targeting of nonresponding lesions may be a reasonable approach to extend benefit.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'PETT'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles